Clinical Trials Browser

Active not recruiting × Lutetium × 1 year × Clear all

NCT06379217 2026-03-11

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Phase 1 Active not recruiting

EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

NCT05849298 2026-03-03

PSMACare

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06894511 2026-02-17

PSMAndARPI

Phase 2 Active not recruiting

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT04711135 2026-02-12

NETTER-P

Phase 2 Active not recruiting

11 enrolled 14 charts 1 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma